Evidence map›Paper›PMID 35239725›Full record

ArticlePloS one2022

Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study.

Teppei Miyakawa, Hidetaka Kawamura, Michitaka Honda, Yoshinao Takano, Shunji Kinuta, Takahiro Kamiga, Shigeru Yamazaki, Atsushi Muto, Satoru Shiraso, Naoyuki Yamashita and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Prognostic biomarkers in metastatic colorectal cancer: delta prognostic nutritional index, delta neutrophil to lymphocyte ratio, and delta platelet to lymphocyte ratio.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Teppei MiyakawaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Fukushima, Japan.ORCID 0000-0002-7481-9559
Hidetaka KawamuraDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Fukushima, Japan.
Michitaka HondaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Fukushima, Japan.
Yoshinao TakanoDepartment of Surgical Oncology, Southern Tohoku General Hospital, Southern Tohoku Research Institute for Neuroscience, Koriyama, Fukushima, Japan.
Shunji KinutaDepartment of Surgery, The Takeda Healthcare Foundation Takeda General Hospital, Aizu Wakamatsu, Fukushima, Japan.
Takahiro KamigaDepartment of Surgery, Shirakawa Kosei General Hospital, Shirakawa, Fukushima, Japan.
Shigeru YamazakiDepartment of Surgery, Ohta Nishinouchi Hospital, Koriyama, Fukushima, Japan.
Atsushi MutoDepartment of Surgery, Fukushima Rosai Hospital, Iwaki, Fukushima, Japan.
Satoru ShirasoDepartment of Surgery, Iwaki Kyoritsu General Hospital, Iwaki, Fukushima, Japan.
Naoyuki YamashitaDepartment of Surgery, Tsuboi Hospital, Koriyama, Fukushima, Japan.
Toshiyasu IwaoDepartment of Gastroenterology, Aidu Chuo Hospital, Aizu Wakamatsu, Fukushima, Japan.
Koji KonoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Fukushima, Japan.
Shinichi KonnoDepartment of Orthopedic Surgery, School Medicine, Fukushima Medical University, Fukushima, Japan.
Fukushima Medical University · JPGunma Chuo Hospital · JPIjinkai Takeda General Hospital · JPIwaki Kyoritsu General Hospital · JPOhta Nishinouchi Hospital · JPSouthern Tohoku General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are a few established prognostic factors for stage IV colorectal cancer. Thus, this study aimed to evaluate the impact of histological subtypes on prognosis and metastatic patterns in patients with stage IV colorectal cancer.

methodsThis was a population-based, multicenter, cohort study. We included consecutive patients diagnosed with stage IV colorectal cancer between 2008 and 2015 at all designated cancer hospitals in Fukushima prefecture, Japan. Patients were classified into two groups according to histological subtypes as follows: poorly differentiated adenocarcinoma (Por), mucinous adenocarcinoma (Muc), or signet-ring cell carcinoma (Sig) and well (Wel) or moderately differentiated adenocarcinoma (Mod). We evaluated the relationship between these histological groups and survival time. After adjusting for other clinical factors, we calculated the hazard ratio for Por/Muc/Sig.

resultsA total of 1,151 patients were enrolled, and 1,031 and 120 had Wel/Mod and Por/Muc/Sig, respectively. The median overall survival was 19.2 and 11.9 months for Wel/Mod and Por/Muc/Sig, respectively (p < 0.001). The adjusted hazard ratio for Por/Muc/Sig with regard to survival time was 1.42 (95% confidence interval: 1.13-1.77). Por/Muc/Sig had a lower incidence of liver and lung metastases and a higher incidence of peritoneal dissemination and metastasis to rare organs, such as the bone and brain.

conclusionsThe Por/Muc/Sig histological subtype was an independent prognostic factor for poor prognosis among patients with stage IV colorectal cancer. The histological subtype may be useful for predicting the prognosis of patients with stage IV colorectal cancer and designing the treatment strategy.

Indexed as

AdenocarcinomaCarcinoma, Signet Ring CellColorectal NeoplasmsCohort StudiesHumansNeoplasm StagingPrognosis

Identifiers

PMID35239725
PMCPMC8893698
OpenAlexW4214832747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.